Halozyme Enters Exclusive Collaboration with Takeda for ENHANZE® Technology
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 08 2026
0mins
Should l Buy HALO?
Source: Newsfilter
- Collaboration Agreement: Halozyme entered a global collaboration and exclusive licensing agreement with Takeda in December 2025, granting Takeda access to ENHANZE® drug delivery technology, which is expected to enhance treatment efficacy and improve patient experiences.
- Market Potential: With over 10 million people projected to live with inflammatory bowel disease (IBD) in the next decade, this collaboration aims to expand the application of vedolizumab, addressing the growing market demand.
- Financial Benefits: Under the agreement, Takeda will make an upfront payment and potential future development and commercial milestone payments to Halozyme, which will also receive low to mid-single-digit royalties on sales of vedolizumab products combined with ENHANZE®, enhancing the company's revenue streams.
- Technological Innovation: Halozyme's ENHANZE® technology has been utilized in ten commercialized products across over 100 global markets, and future advancements through Hypercon™ technology are expected to further improve drug delivery efficiency and expand market opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HALO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HALO
Wall Street analysts forecast HALO stock price to rise
5 Analyst Rating
3 Buy
1 Hold
1 Sell
Moderate Buy
Current: 76.920
Low
56.00
Averages
78.50
High
90.00
Current: 76.920
Low
56.00
Averages
78.50
High
90.00
About HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Halozyme Acquires Three Biotech Startups for $1.3 Billion
- Accelerated Acquisition Activity: Halozyme has recently spent up to $1.3 billion acquiring three biotech startups, indicating its intent to expand in the biopharma sector, which is expected to enhance its market competitiveness.
- Drug Delivery Innovation: The acquisition of hyper-concentration technology allows Halozyme to deliver drugs in smaller volumes, significantly improving patient experience and reducing stress on the healthcare system by enabling quicker administration.
- Optimistic Market Outlook: The CEO of Halozyme noted that M&A activity in the biotech sector is forecasted to accelerate in 2026, reflecting increased confidence in innovative drugs and driving the company's proactive strategies in drug development and marketing.
- Revenue Growth Potential: Halozyme's current technologies have received 10 approvals and are projected to generate $1 billion in royalty revenues by 2026, showcasing its strong profitability and market demand in the drug delivery space.
See More
Tech Stocks Struggle While Consumer Staples Shine
- Tech Sector Weakness: On Tuesday, tech stocks like AMD and Lumentum struggled, leading to a bearish market sentiment that reflects investor concerns over high valuations, potentially impacting future investment decisions.
- Consumer Staples Resilience: In stark contrast to tech stocks, the consumer staples sector showed strong performance, indicating a market preference for stable earnings, which may attract more capital into this area to mitigate risk.
- Regional Banks' Steady Growth: Regional banks demonstrated resilience amid market volatility, drawing investor attention and suggesting that traditional financial institutions remain attractive in uncertain economic conditions, potentially driving their stock prices higher.
- Precious Metals and Industrials Recovery: The strong performance of precious metals and industrials indicates an increased demand for safe-haven assets, reflecting investor concerns about potential economic slowdowns, which could influence investment strategies in related sectors.
See More
Halozyme Raises 2026 Revenue Guidance and Acquires Surf Bio
- Revenue Guidance Increase: Halozyme raised its 2026 revenue guidance to $1.71 to $1.81 billion, reflecting a growth of 23% to 30%, surpassing the analyst estimate of $1.69 billion, indicating strong market performance and growth potential.
- Earnings Per Share Forecast Boost: The company now expects adjusted earnings per share of $7.75 to $8.25 for 2026, up from the previous estimate of $6.50 to $7.00, showcasing enhanced profitability and increased market confidence.
- Surf Bio Acquisition: Halozyme announced the acquisition of Surf Bio for up to $400 million, which includes an upfront payment of $300 million and milestone payments of up to $100 million, aimed at expanding its drug delivery opportunities and strengthening its competitive position.
- Positive Stock Market Reaction: Following the announcement of its preliminary 2025 estimates, Halozyme's shares rallied 3%, and the stock has risen 29% over the past 12 months, reflecting growing investor confidence in the company's future prospects.
See More
Halozyme Raises 2026 Financial Guidance Amid Strong Growth
- Guidance Upgrade: Halozyme raised its 2026 total revenue guidance from $1.43-$1.53 billion to $1.71-$1.81 billion, anticipating a year-over-year growth rate of 23%-30%, highlighting the company's robust long-term growth potential.
- Strong Sales Outlook: The company projects fiscal 2025 sales between $1.385 billion and $1.4 billion, reflecting a year-over-year increase of 36%-38%, with royalty revenues expected to be $865 million to $870 million, further solidifying its market position.
- EBITDA Expectations: Halozyme forecasts adjusted EBITDA for 2026 to range from $1.125 billion to $1.205 billion, indicating a proactive investment strategy, particularly with approximately $60 million tied to Hypercon and Surf Bio.
- Acquisition-Driven Growth: The company acquired Surf Bio for $300 million upfront, with potential additional milestone payments of up to $100 million, which will enhance its product portfolio and drive future revenue growth.
See More
Halozyme Raises Financial Outlook and Acquires Surf Bio for Up to $400M
- Financial Outlook Upgrade: Halozyme raised its 2025 total revenue forecast to $1.385B-$1.4B, exceeding the consensus estimate of $1.34B by $45M-$60M, indicating strong growth potential with an expected year-over-year increase of 36%-38%.
- Acquisition of Surf Bio: The company announced the acquisition of biopharmaceutical firm Surf Bio for up to $400M, with $300M upfront and up to $100M in milestone payments, enhancing its technological capabilities in the biopharmaceutical sector.
- EPS Guidance Increase: Halozyme raised its non-GAAP diluted EPS outlook from $6.50-$7.00 to $7.75-$8.25, surpassing the market estimate of $8.21, reflecting the positive impact of new investments, particularly the $60M in Hypercon and Surf Bio.
- Technological Innovation: Surf Bio's biologic hyperconcentration technology enables concentrations of up to 500 mg/mL for various therapeutics, including monoclonal antibodies and small molecules, which is expected to promote the adoption of auto-injector delivery methods for at-home or healthcare provider use.
See More
Halozyme Raises 2026 Financial Guidance and Acquires Surf Bio
- 2025 Revenue Estimates: Halozyme anticipates total revenue for 2025 to reach between $1.385 billion and $1.4 billion, reflecting a year-over-year growth of 36% to 38%, which underscores the robust momentum of its core business in the biopharmaceutical sector.
- 2026 Financial Outlook: The company has raised its 2026 total revenue guidance to between $1.71 billion and $1.81 billion, with expected year-over-year growth of 23% to 30%, while projecting royalty revenue to exceed $1 billion, growing at 30% to 35%, indicating sustained market demand and a strong business model.
- Acquisition of Surf Bio: Halozyme acquired Surf Bio for an upfront payment of $300 million, with potential milestone payments up to $400 million, aimed at leveraging its innovative hyperconcentration technology to enhance the delivery of antibodies and biologics, thereby expanding its drug delivery portfolio.
- Strategic Partnership Expansion: In 2025, Halozyme signed three new ENHANZE collaboration agreements and multiple auto-injector development agreements, further strengthening its competitive position in drug delivery and laying the groundwork for future revenue growth.
See More
Halozyme Acquires Three Biotech Startups for $1.3 Billion
- Accelerated Acquisition Activity: Halozyme has recently spent up to $1.3 billion acquiring three biotech startups, indicating its intent to expand in the biopharma sector, which is expected to enhance its market competitiveness.
- Drug Delivery Innovation: The acquisition of hyper-concentration technology allows Halozyme to deliver drugs in smaller volumes, significantly improving patient experience and reducing stress on the healthcare system by enabling quicker administration.
- Optimistic Market Outlook: The CEO of Halozyme noted that M&A activity in the biotech sector is forecasted to accelerate in 2026, reflecting increased confidence in innovative drugs and driving the company's proactive strategies in drug development and marketing.
- Revenue Growth Potential: Halozyme's current technologies have received 10 approvals and are projected to generate $1 billion in royalty revenues by 2026, showcasing its strong profitability and market demand in the drug delivery space.
See More
Tech Stocks Struggle While Consumer Staples Shine
- Tech Sector Weakness: On Tuesday, tech stocks like AMD and Lumentum struggled, leading to a bearish market sentiment that reflects investor concerns over high valuations, potentially impacting future investment decisions.
- Consumer Staples Resilience: In stark contrast to tech stocks, the consumer staples sector showed strong performance, indicating a market preference for stable earnings, which may attract more capital into this area to mitigate risk.
- Regional Banks' Steady Growth: Regional banks demonstrated resilience amid market volatility, drawing investor attention and suggesting that traditional financial institutions remain attractive in uncertain economic conditions, potentially driving their stock prices higher.
- Precious Metals and Industrials Recovery: The strong performance of precious metals and industrials indicates an increased demand for safe-haven assets, reflecting investor concerns about potential economic slowdowns, which could influence investment strategies in related sectors.
See More
Halozyme Raises 2026 Revenue Guidance and Acquires Surf Bio
- Revenue Guidance Increase: Halozyme raised its 2026 revenue guidance to $1.71 to $1.81 billion, reflecting a growth of 23% to 30%, surpassing the analyst estimate of $1.69 billion, indicating strong market performance and growth potential.
- Earnings Per Share Forecast Boost: The company now expects adjusted earnings per share of $7.75 to $8.25 for 2026, up from the previous estimate of $6.50 to $7.00, showcasing enhanced profitability and increased market confidence.
- Surf Bio Acquisition: Halozyme announced the acquisition of Surf Bio for up to $400 million, which includes an upfront payment of $300 million and milestone payments of up to $100 million, aimed at expanding its drug delivery opportunities and strengthening its competitive position.
- Positive Stock Market Reaction: Following the announcement of its preliminary 2025 estimates, Halozyme's shares rallied 3%, and the stock has risen 29% over the past 12 months, reflecting growing investor confidence in the company's future prospects.
See More
Halozyme Raises 2026 Financial Guidance Amid Strong Growth
- Guidance Upgrade: Halozyme raised its 2026 total revenue guidance from $1.43-$1.53 billion to $1.71-$1.81 billion, anticipating a year-over-year growth rate of 23%-30%, highlighting the company's robust long-term growth potential.
- Strong Sales Outlook: The company projects fiscal 2025 sales between $1.385 billion and $1.4 billion, reflecting a year-over-year increase of 36%-38%, with royalty revenues expected to be $865 million to $870 million, further solidifying its market position.
- EBITDA Expectations: Halozyme forecasts adjusted EBITDA for 2026 to range from $1.125 billion to $1.205 billion, indicating a proactive investment strategy, particularly with approximately $60 million tied to Hypercon and Surf Bio.
- Acquisition-Driven Growth: The company acquired Surf Bio for $300 million upfront, with potential additional milestone payments of up to $100 million, which will enhance its product portfolio and drive future revenue growth.
See More
Halozyme Raises Financial Outlook and Acquires Surf Bio for Up to $400M
- Financial Outlook Upgrade: Halozyme raised its 2025 total revenue forecast to $1.385B-$1.4B, exceeding the consensus estimate of $1.34B by $45M-$60M, indicating strong growth potential with an expected year-over-year increase of 36%-38%.
- Acquisition of Surf Bio: The company announced the acquisition of biopharmaceutical firm Surf Bio for up to $400M, with $300M upfront and up to $100M in milestone payments, enhancing its technological capabilities in the biopharmaceutical sector.
- EPS Guidance Increase: Halozyme raised its non-GAAP diluted EPS outlook from $6.50-$7.00 to $7.75-$8.25, surpassing the market estimate of $8.21, reflecting the positive impact of new investments, particularly the $60M in Hypercon and Surf Bio.
- Technological Innovation: Surf Bio's biologic hyperconcentration technology enables concentrations of up to 500 mg/mL for various therapeutics, including monoclonal antibodies and small molecules, which is expected to promote the adoption of auto-injector delivery methods for at-home or healthcare provider use.
See More
Halozyme Raises 2026 Financial Guidance and Acquires Surf Bio
- 2025 Revenue Estimates: Halozyme anticipates total revenue for 2025 to reach between $1.385 billion and $1.4 billion, reflecting a year-over-year growth of 36% to 38%, which underscores the robust momentum of its core business in the biopharmaceutical sector.
- 2026 Financial Outlook: The company has raised its 2026 total revenue guidance to between $1.71 billion and $1.81 billion, with expected year-over-year growth of 23% to 30%, while projecting royalty revenue to exceed $1 billion, growing at 30% to 35%, indicating sustained market demand and a strong business model.
- Acquisition of Surf Bio: Halozyme acquired Surf Bio for an upfront payment of $300 million, with potential milestone payments up to $400 million, aimed at leveraging its innovative hyperconcentration technology to enhance the delivery of antibodies and biologics, thereby expanding its drug delivery portfolio.
- Strategic Partnership Expansion: In 2025, Halozyme signed three new ENHANZE collaboration agreements and multiple auto-injector development agreements, further strengthening its competitive position in drug delivery and laying the groundwork for future revenue growth.
See More
